BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEBThe offering is expected to close on September 27, 2024, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
WEB20 hours ago — BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.
BioAge stock rallies 29% following upsized $198M IPO
WEB1 day ago — BioAge Labs (NASDAQ:BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Shares of BioAge recently sold ...
BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEB2 days ago — In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less underwriting discounts ...
BioAge valued at $758 million in debut as investors bet on
WEB1 day ago — BioAge valued at $758 million in debut as investors bet on weight-loss drug frenzy. (Reuters) - Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong ...
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
WEB1 day ago — BioAge Labs is having its initial public offering today. The drug developer’s signature product, Azelaprag, isn’t yet on sale, but it is undergoing clinical trials in hopes it will one day be.
BioAge prices $198M IPO, validating pivot to obesity drug research
WEB2 days ago — BioAge Labs has raised $198 million in an initial public offering, the company announced Wednesday, capitalizing on intense investor interest in drugs that can promote weight loss. BioAge, which is evaluating a medicine that’s meant to boost the effects of popular obesity drugs known as GLP-1 agonists, sold 11 …
Obesity drug developer BioAge Labs aims up to $640 mln …
WEB2 days ago — Sept 25 (Reuters) - BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign ...
BioAge seeks nearly $200 million in initial public offering
WEB2 days ago — BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close to $200 million through an initial public offering. The Richmond ...
BioAge Labs Files For $100M IPO, Becomes The New Entrant In …
WEBSep 4, 2024 — BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015...
- Some results have been removed